Product Details
What We’ve Learned Since Scott Gottlieb Was Confirmed
FDA’s new Commissioner, Dr. Scott Gottlieb, isn’t letting grass grow beneath his feet. With a new occupant in the White House and a new philosophy in Congress, change is in the air. And this is only the beginning.
FDAnews has assembled a standout panel — five top experts, four of them ex-FDAers — to bring their insights to bear on how the Gottlieb FDA will impact your products and programs. In this first-of-four installments, expect a glimpse of:
- What the Trump-Gottlieb FDA is likely to continue and what will likely change...
- What’s going on behind closed doors — unannounced priorities Gottlieb & Co. can be expected to cook up...
- Guidances, regulation, enforcement: What lies ahead...
- Specific, practical guidance to help you prepare, based on Dr. Gottlieb’s record and regulatory inclinations as well as unfolding events...
- How to plan now to achieve your goals for 2017, 2018 and beyond...
Plan to tune in once a month every month through December to learn more as events unfold in real time. Other installments include:
- Device Regulation under Gottlieb & Trump
- Pharmaceutical Regulation under Gottlieb-Trump
- The FDA Under Gottlieb-Trump and a Look Ahead
Given the fluid nature of events though, panelists are sure to range beyond the topic of the day.